In September 2024, California quietly set a precedent. Lawmakers passed SB 1223, an amendment to the California Consumer Privacy Act (CCPA) that classifies neural data as “sensitive personal information.” For the first time in U.S. law, brain-derived signals such as electroencephalography (EEG) traces, functional MRI (fMRI) scans (a type of MRI imaging that measures and maps brain activity) or brain-computer interface (BCI) activity are treated as a category apart from other forms of biodata. The move may seem technical, but it signals a new public expectation: if companies intend to touch the brain, they will be held to stricter standards of stewardship, purpose limitation, and user control.
This is a threshold moment for neuroethics. It invites us to move beyond dystopian speculation ab

MedCity News

Raw Story
Local News in New York
America News
Local News in New Jersey
Reuters US Business
The Daily Beast
AlterNet